QL2108 injection

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Atopic Dermatitis

Phase 1

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

CompletedNCT06614907

Qilu Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2024-08-31End: 2024-12-27Updated: 2025-03-12

Phase 3

A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Not yet recruitingNCT06884891

Qilu Pharmaceutical Co., Ltd.Atopic Dermatitis

Start: 2025-04-30End: 2028-04-30Target: 520Updated: 2025-03-21